Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease

Jill K. Morris, Roxanne Adeline Z. Uy, Eric D. Vidoni, Heather M. Wilkins, Ashley E. Archer, John P. Thyfault, John M. Miles, Jeffrey M. Burns

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Alzheimer's disease (AD) may have heterogeneous pathophysiological underpinnings, with risk factors including apolipoprotein rmvarep4 (APOE4) genotype and insulin resistance. We hypothesized that distinct phenotypes exist within AD. We examined APOE4 and metabolic biomarkers in 338 subjects (n = 213 nondemented (ND), n = 125 AD). We further characterized steady state free fatty acid (FFA) levels in a subset of 45 participants who had also participated in a hyperinsulinemic-euglycemic clamp. Insulin resistance (HOMA-IR) was elevated in AD versus ND (p = 0.04) and in APOE4 noncarriers versus carriers (p < 0.01). This was driven by increased fasting insulin in AD versus ND (p < 0.01) and in APOE4 non-carriers versus carriers (p = 0.01). Fasting glucose was not different. In subjects who underwent a clamp, there was a group x genotype interaction on FFA levels during hyperinsulinemia (p = 0.03). APOE4 non-carriers with AD had higher FFA levels, while APOE4 carriers with AD exhibited lower FFA levels. Metabolic dysfunction is overrepresented in individuals with AD dementia who do not carry the APOE4 allele. This suggests that important subsets of AD phenotypes may exist that diverge metabolically.

Original languageEnglish (US)
Pages (from-to)1129-1135
Number of pages7
JournalJournal of Alzheimer's Disease
Volume58
Issue number4
DOIs
StatePublished - 2017
Externally publishedYes

Fingerprint

Alzheimer Disease
Apolipoproteins
Biomarkers
Genotype
Nonesterified Fatty Acids
Insulin Resistance
Fasting
Phenotype
Glucose Clamp Technique
Hyperinsulinism
Alleles
Insulin
Glucose

Keywords

  • Alzheimer's disease
  • apolipoprotein E
  • hyperinsulinemia
  • insulin
  • insulin resistance

ASJC Scopus subject areas

  • Clinical Psychology
  • Geriatrics and Gerontology
  • Psychiatry and Mental health

Cite this

Morris, J. K., Uy, R. A. Z., Vidoni, E. D., Wilkins, H. M., Archer, A. E., Thyfault, J. P., ... Burns, J. M. (2017). Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease. Journal of Alzheimer's Disease, 58(4), 1129-1135. https://doi.org/10.3233/JAD-170148

Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease. / Morris, Jill K.; Uy, Roxanne Adeline Z.; Vidoni, Eric D.; Wilkins, Heather M.; Archer, Ashley E.; Thyfault, John P.; Miles, John M.; Burns, Jeffrey M.

In: Journal of Alzheimer's Disease, Vol. 58, No. 4, 2017, p. 1129-1135.

Research output: Contribution to journalArticle

Morris, JK, Uy, RAZ, Vidoni, ED, Wilkins, HM, Archer, AE, Thyfault, JP, Miles, JM & Burns, JM 2017, 'Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease', Journal of Alzheimer's Disease, vol. 58, no. 4, pp. 1129-1135. https://doi.org/10.3233/JAD-170148
Morris, Jill K. ; Uy, Roxanne Adeline Z. ; Vidoni, Eric D. ; Wilkins, Heather M. ; Archer, Ashley E. ; Thyfault, John P. ; Miles, John M. ; Burns, Jeffrey M. / Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease. In: Journal of Alzheimer's Disease. 2017 ; Vol. 58, No. 4. pp. 1129-1135.
@article{036f56d95a4e4ccb9fff237cfd3408ab,
title = "Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease",
abstract = "Alzheimer's disease (AD) may have heterogeneous pathophysiological underpinnings, with risk factors including apolipoprotein rmvarep4 (APOE4) genotype and insulin resistance. We hypothesized that distinct phenotypes exist within AD. We examined APOE4 and metabolic biomarkers in 338 subjects (n = 213 nondemented (ND), n = 125 AD). We further characterized steady state free fatty acid (FFA) levels in a subset of 45 participants who had also participated in a hyperinsulinemic-euglycemic clamp. Insulin resistance (HOMA-IR) was elevated in AD versus ND (p = 0.04) and in APOE4 noncarriers versus carriers (p < 0.01). This was driven by increased fasting insulin in AD versus ND (p < 0.01) and in APOE4 non-carriers versus carriers (p = 0.01). Fasting glucose was not different. In subjects who underwent a clamp, there was a group x genotype interaction on FFA levels during hyperinsulinemia (p = 0.03). APOE4 non-carriers with AD had higher FFA levels, while APOE4 carriers with AD exhibited lower FFA levels. Metabolic dysfunction is overrepresented in individuals with AD dementia who do not carry the APOE4 allele. This suggests that important subsets of AD phenotypes may exist that diverge metabolically.",
keywords = "Alzheimer's disease, apolipoprotein E, hyperinsulinemia, insulin, insulin resistance",
author = "Morris, {Jill K.} and Uy, {Roxanne Adeline Z.} and Vidoni, {Eric D.} and Wilkins, {Heather M.} and Archer, {Ashley E.} and Thyfault, {John P.} and Miles, {John M.} and Burns, {Jeffrey M.}",
year = "2017",
doi = "10.3233/JAD-170148",
language = "English (US)",
volume = "58",
pages = "1129--1135",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "4",

}

TY - JOUR

T1 - Effect of APOE ϵ4 Genotype on Metabolic Biomarkers in Aging and Alzheimer's Disease

AU - Morris, Jill K.

AU - Uy, Roxanne Adeline Z.

AU - Vidoni, Eric D.

AU - Wilkins, Heather M.

AU - Archer, Ashley E.

AU - Thyfault, John P.

AU - Miles, John M.

AU - Burns, Jeffrey M.

PY - 2017

Y1 - 2017

N2 - Alzheimer's disease (AD) may have heterogeneous pathophysiological underpinnings, with risk factors including apolipoprotein rmvarep4 (APOE4) genotype and insulin resistance. We hypothesized that distinct phenotypes exist within AD. We examined APOE4 and metabolic biomarkers in 338 subjects (n = 213 nondemented (ND), n = 125 AD). We further characterized steady state free fatty acid (FFA) levels in a subset of 45 participants who had also participated in a hyperinsulinemic-euglycemic clamp. Insulin resistance (HOMA-IR) was elevated in AD versus ND (p = 0.04) and in APOE4 noncarriers versus carriers (p < 0.01). This was driven by increased fasting insulin in AD versus ND (p < 0.01) and in APOE4 non-carriers versus carriers (p = 0.01). Fasting glucose was not different. In subjects who underwent a clamp, there was a group x genotype interaction on FFA levels during hyperinsulinemia (p = 0.03). APOE4 non-carriers with AD had higher FFA levels, while APOE4 carriers with AD exhibited lower FFA levels. Metabolic dysfunction is overrepresented in individuals with AD dementia who do not carry the APOE4 allele. This suggests that important subsets of AD phenotypes may exist that diverge metabolically.

AB - Alzheimer's disease (AD) may have heterogeneous pathophysiological underpinnings, with risk factors including apolipoprotein rmvarep4 (APOE4) genotype and insulin resistance. We hypothesized that distinct phenotypes exist within AD. We examined APOE4 and metabolic biomarkers in 338 subjects (n = 213 nondemented (ND), n = 125 AD). We further characterized steady state free fatty acid (FFA) levels in a subset of 45 participants who had also participated in a hyperinsulinemic-euglycemic clamp. Insulin resistance (HOMA-IR) was elevated in AD versus ND (p = 0.04) and in APOE4 noncarriers versus carriers (p < 0.01). This was driven by increased fasting insulin in AD versus ND (p < 0.01) and in APOE4 non-carriers versus carriers (p = 0.01). Fasting glucose was not different. In subjects who underwent a clamp, there was a group x genotype interaction on FFA levels during hyperinsulinemia (p = 0.03). APOE4 non-carriers with AD had higher FFA levels, while APOE4 carriers with AD exhibited lower FFA levels. Metabolic dysfunction is overrepresented in individuals with AD dementia who do not carry the APOE4 allele. This suggests that important subsets of AD phenotypes may exist that diverge metabolically.

KW - Alzheimer's disease

KW - apolipoprotein E

KW - hyperinsulinemia

KW - insulin

KW - insulin resistance

UR - http://www.scopus.com/inward/record.url?scp=85021298436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021298436&partnerID=8YFLogxK

U2 - 10.3233/JAD-170148

DO - 10.3233/JAD-170148

M3 - Article

C2 - 28550261

AN - SCOPUS:85021298436

VL - 58

SP - 1129

EP - 1135

JO - Journal of Alzheimer's Disease

JF - Journal of Alzheimer's Disease

SN - 1387-2877

IS - 4

ER -